DETECSEPSNCT07942272
Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (18)
Show 13 moreShow less
Arms and interventions
Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol. Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below : * If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation. * If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required. * In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.
Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.
Other: Plasma H3.1 concentration, NEWS2 score
Sites
5 sites in 1 country